Process patent legislation
Executive Summary
The House passed Rep. Kastenmeier's (D-Wis.) measure (HR 4899) under suspension of the rules, and the Senate Judiciary Committee passed Sen. Mathias' (R-Md.) legislation (S 1543) unanimously on Sept. 19. Although the Mathias bill is viewed as a compromise between the brandname and generic drug industries, Kastenmeier told the House he "had to reject" its provisions due to the "impact of such proposals on nonpharmaceutical industry process patent holders, workability, and fairness to patent holders." He noted that the Reagan Administration shares his concerns ("The Pink Sheet" Sept. 15, p. 12), but added that he hopes "our differences with the other body can be reconciled before adjournment".
You may also be interested in...
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.